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Abstract
Background: Gliomatosis peritonei (GP) is a rare condition characterized by mature glial tissue implants widespread
in the peritoneum. The GP is often associated with ovarian teratoma. However, little is known about the characteristics
and prognosis of GP. The purpose of this study was to describe the features, treatment, and prognosis of GP.
Additionally, we review previously reported cases of GP, summarizing the presently known data.
Methods: From January 2000 to January 2016, cases of ovarian teratoma and GP treated at Peking Union Medical
College Hospital were reviewed. We assessed the pathology, treatments, and outcomes along with prognostic
information. Additionally, the literature regarding this clinical condition was also reviewed.
Results: Eight patients met the inclusion criteria. Patients had a median age of 20 (range, 15–25) years. GP was
diagnosed as the primary tumor in 6 patients and at a secondary surgery in two patients. The primary ovarian
tumor consisted of immature teratoma (n = 7) and mature teratoma (n = 1). Grades of immature ovarian teratoma were
2, grade 1; 3, grade 2; and 2, grade 3. Tumors mean had a size of 20.4 (range, 11–30) cm. The median follow-up time
was 60.5 (range, 3–144) months. All cases had conservative surgery and seven of them had macroscopic residual
disease postoperatively. During the study period, the eight patients remained alive and asymptomatic. Three patients
in the study experienced spontaneous pregnancy. After reviewing the existing literature, a total of 14 patients with
nodal gliomatosis were present and 10 of them were alive. According to the literature review, five articles reported
more than five cases. Of a total of 67 patients, 60 of them remained alive.
Conclusion: The prognosis of immature ovarian teratoma with GP is favorable. Complete resection of GP is often
difficult. Residual peritoneal disease in GP can be asymptomatic and quiescent over a long period. A more conservative
surgical approach may be carried out in patients with massive peritoneal spread after the presence of metastatic
immature elements is excluded. Owing to the risk of recurrence and malignant transformation of GP, a long-term
follow-up is necessary for patients with residual peritoneal disease.
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Background
Gliomatosis peritonei (GP) is a rare disease character-
ized by many peritoneal and omental implants com-
posed of mature glial tissue. It is mainly associated with
ovarian teratomas, especially in immature ovarian tera-
toma. Thus far, only about 100 cases have been reported
[1]. According to the WHO grading system for imma-
ture ovarian teratoma, GP is considered as grade 0. In
fact, GP has long been associated with good prognosis.
Because of its rarity, the prognostic effect of GP and its
clinical characteristics remain to be clarified. In the
present study, we report eight cases of GP diagnosed
and treated at our hospital. We also reviewed the rele-
vant literature to increase the understanding of this
disease.
Methods
From January 2000 to January 2016, cases of ovarian
teratoma with GP diagnosed at Peking Union Medical
College Hospital were reviewed. Medical and patho-
logical records were retrospectively reviewed to evaluate
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the clinical features of all patients. Patients were in-
cluded in the study if they met the following criteria:
histological review of the first tumor by an expert path-
ologist; diagnosis of ovarian teratoma (mature or imma-
ture), excluding other malignant germ cell tumors; For
patients who received adjuvant chemotherapy after sur-
gery, immature teratoma (IMT) associated with GP at
the secondary surgery were excluded; patients whose
follow-up information was intact. The relevant literature
was reviewed simultaneously.
Ovarian teratomas were graded according to the pub-
lished guidelines. Peritoneal nodal specimens were carefully
examined to exclude the co-existence of metastatic imma-
ture elements. The precise surgical details were recorded.
Oncologic and pregnancy outcome were analyzed.
All patients had undergone conservative surgery (con-
servation of uterus and at least a portion of an ovary).
Additional surgical procedures, such as peritonectomies,
appendectomy, omentectomy, and lymphadenectomy
were performed depending on the stage and macro-
scopic situation during the operation. Some patients
underwent a second surgery.
Adjuvant chemotherapy was given because of tumor rup-
ture, stage IC, or advanced stage or high grade of teratoma
(grade 2 or grade 3) according to the NCCN guideline.
Follow-up was based on clinical examination and radiologic
imaging. Patient information was updated until April 2016
with a median follow-up of 60.5 (range: 3–144) months.
Results
During the study period, eight patients that presented at
our hospital met the inclusion criteria (shown in Fig. 1).
The patients’ clinical and pathological features are pre-
sented in Table 1. Patients had a median age of 20
(range: 15–25) years. The mean size of tumors was 20.4
(range: 11–30) cm. In the present study, seven primary
ovarian tumors were immature teratomas (n = 7; grade
1, 2; grade 2, 3; and grade 3, 2) (Fig. 2 a, b), and one was
a mature teratoma (n = 1) (Fig. 2c, d). The level of blood
CA125 before therapy was available in seven patients,
with a median CA125 level of 340.3 U/ml (range: 98.9–
673.5 U/ml).
Six patients had undergone comprehensive staging
surgery, which led to the diagnosis of GP (Fig. 2e). The
other two patients underwent unilateral cystectomy as
the first surgery and GP was detected in the secondary
surgery (cases 4 and 5). Seven patients had residual dis-
ease postoperatively.
In case 4, the patient presented with abdominal disten-
sion, abdominal pain, nausea, and vomiting. The B ultra-
sound showed a 14-cm cystic-solid pelvic mass. She
underwent a unilateral cystectomy and was diagnosed
with immature ovarian teratoma (grade 2). Subsequently,
she received three cycles of bleomycin, etoposide, and
cisplatin (PEB). Four months after the completion of
chemotherapy, the computed tomography (CT) showed
masses in Douglas’ pouch and on the liver surface with
enlarged pelvic lymph nodes. All tumor markers were
negative before the second surgery. Second surgery
showed numerous miliary nodules on the surface of the
intestine and masses of about 3 to 5 cm in Douglas’
pouch. The implants were so dispersed that complete re-
section of the tumors was impossible. Frozen section of
the mass in Douglas pouch showed mature glial
Fig. 1 Summarized figure of ovarian teratoma with GP
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elements without immature tissues. Thus, growing tera-
toma syndrome (GTS) was diagnosed. After the diagno-
sis of GP, she did not receive further therapy. She was
remained alive with persisting but asymptomatic disease
32 months after the diagnosis of GP (36 months after
the diagnosis of immature ovarian teratoma).
In case 5, the patient underwent laparoscopic cystec-
tomy because of ovarian cyst at another hospital. The
pathologic evaluation indicated the presence of imma-
ture teratoma (grade 2). However, she was not given
chemotherapy at that time. Six months after the first
surgery, she suffered from recurrence of the ovarian cyst.
A second laparoscopic surgery was performed, revealing
both ovarian cysts, as well as peritoneal and pelvic wall
implants. Laparoscopic cystectomy was performed. Sur-
gical pathology showed mature teratoma, associated with
GP. Ten months later, a CT showed multiple masses
in the abdominopelvic cavity, near the liver and
spleen. The surgical procedure consisted of a subopti-
mal cytoreduction. After the second surgery, the
pathologic evaluation of resected tissue showed ma-
ture teratoma and mature peritoneal gliomatosis. She
remained alive and asymptomatic 53 months after the
diagnosis of GP (61 months after the diagnosis of ma-
ture ovarian teratoma).
Four cases (case 2, 3, 6, and 8) of nodal gliomatosis
were detected in form of glial tissue in the pelvic lymph
nodes (Fig. 2f ). A summary of the cases of nodal glioma-
tosis is presented in Table 2. A total of 14 patients with
nodal gliomatosis were described and 10 remained alive
at the time of the last follow-up. Most of the published
papers on GP were case reports. Only 5 articles in the
literature reported more than five cases (Table 3). For a
total of 67 patients, 60 of them were still alive at the
time of the last follow-up.
Five patients were given chemotherapy (PEB or bleo-
mycin, vincristine, and cisplatin [PVB]). If the dose of
bleomycin reached the lifetime dose, the chemotherapy
regimen was changed to PE or PV by omitting bleo-
mycin. Immunohistochemical staining for glial fibrillary
acidic protein (GFAP) was available in three cases. All
three cases were positive for GFAP (Fig. 3a). Two of
them were positive for S-100 protein (Fig. 3b). Three pa-
tients (cases 5, 6, and 8) in our group experienced a
spontaneous pregnancy.
Discussion
The metastatic implantation of mature glial tissue on
the surface of the peritoneum, omentum, and abdominal
lymph nodes is defined as GP. In a clinical setting, these
widespread peritoneal, grayish tan-colored, tiny nodules
encountered intraoperatively may be misdiagnosed as
ovarian carcinomas or peritoneal tuberculosis. Ideal op-
timal resection may not be achieved in such cases with
widespread implantation. However, GP has a favorable
prognosis. In the report by Yoon et al., the overall sur-
vival did not differ between immature ovarian teratomas
with GP and immature ovarian teratomas without GP,
though patients with GP presented more frequent recur-
rence and shorter recurrence-free survival [2]. All pa-
tients (15 cases with GP) except one are currently alive
when the articles were published.
GP is often diagnosed on HE-stained tissue sections,
and its differentiation with low-grade epithelial ovarian
tumors was difficult. A positive staining reaction of glial
tissue for the neural marker, GFAP, is helpful. GFAP







Surgical Procedure (1st surgery) Primary
tumor
Metastatic Tissue






1 23 420.1 18 USO, Peritonectomies, Appendectomy,
omenctomy
IMT, G1 GP PEB*3 NA YES Alive
16 months




NO + YES Alive
3 months
3 16 340.4 20 USO, Peritonectomies, Omenctomy,
lymphadenectomy
IMT, G2 GP, Nodal,
gliomatosis
PEB*6 + YES Alive
68 months
4 18 171.7 14 cystectomy IMT, G2 NA PEB*3 NA YES Alive
38 months
5 23 NA 11 cystectomy IMT, G2 NA NO NA YES Alive
61 months
6 22 381.1 25 USO, Peritonectomies, Omenctomy,
lymphadenectomy
IMT, G1 GP, Nodal,
gliomatosis
NO + YES Alive
60 months








8 17 238.7 30 USO, Peritonectomies, Omenctomy,
Lymphadenectomy, Appendectomy
IMT, G3 GP, Nodal,
gliomatosis
PEB*4 NA YES Alive
144 months
GFAP glial fibrillary acidic protein, GP gliomatosis peritonei, IMT immature teratoma, MT mature teratoma, NA not available, USO unilateral salpingo-oophorectomy,
PEB bleomycin, etoposide, cisplatin, PVB bleomycin, vincristine,cisplatin, PV vincristine,cisplatin
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immunostain confirmed the glial nature of the tissue. A
strong expression often suggests tumor cells are mature
and well differentiated [3].
The etiology of GP is largely unknown. According to
previous reports, there are two theories about the devel-
opment of GP. One relates to capsular defects of the pri-
mary teratoma or dissemination via angiolymphatic
channels. In some cases, GP within the omentum imme-
diately adjacent to a capsular defect supports the mech-
anism of spread in its inception [4]. In 11 of the 12 cases
in Robboy’s report, the capsule either had a tear or was
adherent to the omentum or adnexal structure [5]. In
support of lymphatic dissemination, mature glial tissue
has been presented in para-aortic and pelvic lymph
nodes with or without the presence of GP (Table 2). In
some reports, GP was only found in the second surgery
(as in case 4 in the present study). Kim et al. reviewed
about 100 cases in the literature and found 9 cases of
nodal gliomatosis in the pelvic or para-aortic lymph
nodes with or without the presence of GP [6]. However,
in their literature review, there were three cases of nodal
gliomatosis presented as grades 1 to 3. As the nodal im-
plantation contained immature elements, these should
not be considered as nodal gliomatosis but as metastasis
of the immature teratoma.
The other theory suggests that glial foci are genetically
unassociated with teratoma. In Ferguson’s study [7], they
use polymorphic microsatellite (MS) loci in two cases to
address the origin of GP. They found that glial implants
and normal tissue showed heterozygosity, while the tera-
toma showed homozygosity at the same MS loci. Their
findings indicated that glial implants in GP were unrelated
Fig. 2 Immature neuroepithelial tissue in the form of neuroectodermal rosettes are admixed with mature tissues a HE stain × 40. Immature
neuroectodermal tissue b HE stain × 200. Ovarian mature teratoma is composed of various tissue components like skin and skin appendages c,
cartilage d HE stain × 40. Peritoneal gliomatosis showing a discrete nodule of mature glial tissue, which surrounded by fibroadipose tissue of
peritoneum e HE stain × 40. Mature glial tissue is seen in right iliac lymph node f HE stain × 40
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to the ovarian teratoma and arise from normal cells such
as pluripotent Müllerian stem cells. It is possible that peri-
toneal stem cells can differentiate into glial cells under the
stimulation of some factors secreted by teratomas [8]. The
occurrence of GP after ventriculoperitoneal shunt opera-
tions when glial tissue is transported from cerebrospinal
fluid into peritoneal cavity via shunt further support this
theory [9]. However, the detailed mechanisms by which
subperitoneal cells develop into glial follicles remain to be
determined.
The stage and grade of the primary teratoma and the
grade of its metastatic tumor are related to the prog-
nosis of teratoma. Robboy and Scully reviewed the
literature and presented a large series of cases [5].
They found that the prognoses in metastasized ovarian
teratomas, or in ovarian teratomas leading to periton-
eal implants, are favorable when the implants are com-
posed of fully mature glial tissue. Müller reviewed all
cases of GP published between 1906 and 2002. Eleven
cases showed adverse outcomes [1]. They found that
the recurrence of disease was associated with lack of
extensive histological sampling at the first surgery.
Thus, all specimens need to be adequately sampled
and multiple biopsies should be taken to exclude im-
mature glial tissue or teratoma elements. Once the
presence of immature teratoma is confirmed in the
Table 2 Summary of nodal gliomatosis cases reported in the literatures
Authors Age LN sites Primary tumor Treatment Outcome
Benirschke [16], 1960 18 ys Retroperitoneal,ilac,cervical axillary Mature teratoma chemoradiotherapy Dead 8 months
Nagashima [13], 1974 22ys Inguinal, mesenteric, mediastinal, cervical IMT S+ Ch Dead 8 months
Shafie [14] 1984 12 ys Omental MT S+ Ch NR 5 ys
Perrone [15] 1986 10 mo Para-arotic IMT G1 Surgery NR 9 months
Khan [17] 2005 23 ys Lymph node IMT G1 S+ Ch NA
Fang [18] 2015 20 ys Para-arotic IMT G3 S+ Ch Alive 36 months
Kim [6] 2013 34 ys Hypogastric IMT G1 S NR 9 months
Li Liang [8] 2015 18 ys Lymph node IMT G1 NA ANED 19 months
42 ys Lymph node MGCT NA AWD 23 months
10 ys Lymph node MGCT NA ANED 11 months
Present study 25 ys iliac MT Surgery Alive 3 months
16 ys Iliac IMT G2 S+ Ch Alive 68 months
22 ys iliac IMT G1 S+ Ch Alive 60 months
17 ys iliac IMT G3 S+ Ch Alive 144 months
ANED alive with no evidence of disease, AWD alive with disease, Ch chemotherapy, IMT immature teratoma, LN lymph node, MT mature teratoma, MGCT mixed
germ cell tumor, NA not available, NR not recurrence, S surgery, ys years
Table 3 Cases of ovarian teratoma associated with GP in studies that reported more than five cases
Authors Cases Median
Age ys
Ovarian neoplasm Diagnosis Recurrence Treatment Follow up
Norris [10], (1976) 7 17 IMT: G1: 5, G2-G3: 2 1st surgery: 7 NA S: 4, S + Ch: 1, S + Rx:2 5 alive, 1 dead,
1 NA
Harms [11], (1989) 13 11.5 IMT: G1:8, G2-G3: 5 1st surgery: 11,
2nd surgery: 2
NO S: 6, S + Ch: 7 13 alive




37.5 %, (6/16) S: 3, S + Ch: 13 15 alive, 1 dead
Bentivegna, [12], (2015)a 9 36 IMT: G1: 5, G2-G3: 4 1st surgery: 1,
2nd surgery: 8
22.2 %, (2/9) S: 5, S + Ch: 4 9 alive
Liang [8], (2015) 14 NA IMT: G1: 5, G2-G3: 9 1st surgery: 10,
2nd surgery: 4
NA NA 10 alive, NA: 4




NO S: 3, S + Ch: 5 8 alive




17.4 %, (8/46)b S: 21, S + Ch: 30, S + Rx:2,
NA:14
60 alive, 2 dead,
NA: 5
Ch chemotherapy, IMT immature teratoma, MT mature teratoma, NA not available, S surgery, Rx radiotherapy
aOne case in the article (case 8) was consisted of mixed ovarian germ tumor (yolk sac and dysgerminoma and mature teratoma). Thus, the table shows 9 cases
bAs there was no data available in the reference 8 and 10, we just add up the data from the remaining articles
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metastatic tissue, the treatment scheme and prognosis
may change.
Most of the papers on GP are cases. At present there
are only 5 articles which report more than five cases
(Table 3) [2, 8, 10–12]. Most cases of GP are associated
with ovarian teratoma, especially with immature ovarian
teratoma. In Yoon’s report, there were a total of 16 ovar-
ian teratomas associated with GP [2]. Among them, 15
cases were of immature ovarian teratomas of various
grades (4 cases were grade 1; 11 cases were grade 2 or
3). Liang reported the largest series of GP cases so far
[8]. Sixteen of 23 cases were associated with immature
ovarian teratomas. However, immature ovarian teratoma
with GP showed better prognosis than would be ex-
pected based on the grading of the primary immature
teratoma. In Norris’s report, the survival of patients with
grades 1, 2, and 3 were 82 %, 63 %, and 30 %, respect-
ively [10]. In Yoon’s report, all but one case of immature
teratoma with GP remained alive when their report was
published, although GP showed more frequent recur-
rences [2]. In Robboy’s report, 12 patients were alive and
well [5]. More over, the survival of 8 patients in our
series may also indicate that the presence of mature glial
implants does not affect adversely the prognosis of ovar-
ian teratoma.
Presence of glial tissue in lymph nodes is rare. Thus
far, 14 cases have been reported in nine articles [6, 8,
13–18] (Table 2). Based on previous reports, adjuvant
chemotherapy is unnecessary for patients with retroperi-
toneal lymph node metastasis of mature glial tissue. The
prognosis of patients with nodal gliomatosis is favorable.
In our series, patients with nodal gliomatosis remained
alive and well during the follow-up period.
Sometimes immature ovarian teratoma can be associ-
ated with miliary spread of immature implants. After
surgery and chemotherapy, the immature tissue may
transfer into mature tissue. Chemotherapeutic retrocon-
version has also been called growing teratoma syndrome
(GTS) [19]. However, there are some differences be-
tween GP and GTS. First, GP is composed of pure ma-
ture implants in the peritoneum without other mature
nonglial tissues which can be seen in GTS. Second, GP
could be encountered in the first surgery without prior
chemotherapy. At last, the management of these two
terms is quite different. An optimal cytoreduction is rec-
ommended for GTS to avoid complications such as
bowel obstruction and perforation [20]. Because the le-
sions in GP are extensive, complete resection of GP is
usually difficult. Luckily residual peritoneal disease in
GP can be asymptomatic and quiescent over a long
period [12]. Thus, residual implants can be ignored and
the therapy is mainly depended on the stage and grade of
the primary ovarian teratoma. Seven cases in our series
presented macroscopic residual disease at postoperatively,
and all of these patients remained alive and asymptomatic
during the median follow-up of 60.5 months.
Bentivegna reported 10 cases of GP, while six of them
were managed by conservative surgery [12]. All of their
patients were asymptomatic at the time of the last con-
sultation, and half had incomplete resected macroscopic
GP. These authors found residual peritoneal disease
could be totally quiescent over a long period without
any impact on patient outcomes. As ovarian teratoma
mostly occurs in young women who wish to preserve
fertility, it is important to reduce the surgical scope and
reduce surgical trauma without compromising cure rate.
As residual implants of GP can be ignored, a more con-
servative surgical approach may be carried out in pa-
tients with massive peritoneal spread after exclusion of
the presence of metastatic immature elements.
In the review of literature undertaken by Müller (86
cases plus their own two cases) [1], three progressions
were observed: GP was asymptomatic and detected by a
secondary surgery; GP may undergo “fibroblastic trans-
formation” and gradually disappear [21]; GP may trans-
form into malignant glial neoplasms such as glioblastoma
which can result in patient death [22]. In most of the
cases, patients with massive peritoneal spread cannot be
completely resected, but these lesions can be totally quies-
cent over a long period. GP is associated with frequent re-
currence in patients with immature ovarian teratoma [2].
In rare cases, GP showed potential for malignant trans-
formation after several years. Thus, a long period of care-
ful monitoring for patients with GP may be needed.
Fig. 3 Positive immunohistochemical staining of the mature glial tissue with glial glial fibrillary acidic protein immunostain (a) and S 100 (b) × 100
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Conclusion
Gliomatosis peritonei is metastatic implantation of ma-
ture glial tissue on surfaces of peritoneum. It is often
associated with ovarian teratoma of any grade. The prog-
nosis of GP is favorable. Because GP is always present
with massive peritoneal implantation, optimal resection
is difficult. Although residual peritoneal disease can be
totally quiescent over a long period, long-term follow-up
is needed for patients with residual disease. A more con-
servative surgical approach may be carried out in pa-
tients with massive peritoneal spread.
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